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Summary
 
The formation of the repertoire of mouse natural killer (NK) cell receptors for major histo-
compatibility complex (MHC) class I molecules was investigated by determining the develop-
mental pattern of Ly49 receptor expression. During the first days after birth, few or no splenic
NK cells express Ly49A, Ly49C, Ly49G2, or Ly49I receptors. The proportion of Ly49
 
1
 
splenic NK cells gradually rises to adult levels during the first 6–8 wk of life. The appearance of
appreciable numbers of splenic Ly49
 
1
 
 NK cells coincides with the appearance of NK activity at
3–4 wk. After in vivo transfer, NK cells not expressing specific Ly49 receptors can give rise to
NK cells that do, and cells expressing one of these four Ly49 receptors can give rise to cells ex-
pressing others. Once initiated, expression of a Ly49 receptor is stable for at least 10 d after in
vivo transfer. Hence, initiation of Ly49 receptor expression occurs successively. Interestingly,
expression of one of the receptors tested, Ly49A, did not occur after in vivo transfer of Ly49A
 
2
 
cells. One possible explanation for these data is that the order of Ly49 receptor expression by
NK cells is nonrandom. The results provide a framework for evaluating models of NK cell rep-
ertoire formation, and how the repertoire is molded by host class I MHC molecules.
 
N
 
K cell lytic activity is often inhibited by MHC class I
molecules expressed by target cells. It is believed that
this mechanism allows the immune system to destroy cells
that downregulate class I expression due to infection or trans-
formation (1). Most or all natural killer cells in mice express
one or more members of the Ly49 receptor family, a group
of closely related and genetically linked MHC class I–spe-
cific inhibitory receptors (2). The capacity of NK cells to
attack target cells that lack MHC class I expression, while
sparing cells that express self–MHC class I molecules, de-
pends in large part on inhibitory recognition of MHC mol-
ecules by Ly49 receptors.
mAb reagents to some Ly49 receptors have been used to
show that they are expressed on overlapping subsets of nat-
ural killer cells (3–5). An NK cell can express multiple Ly49
receptors, including Ly49 receptors that do not recognize
self–MHC class I molecules. The overall pattern of expres-
sion of different Ly49 receptors suggests that a stochastic
mechanism governs the initial choice of which Ly49 recep-
tors a NK cell expresses (6). Nevertheless, the repertoire is
not wholly stochastic, since the frequencies of NK cells ex-
pressing different Ly49 receptors in a mouse are clearly in-
fluenced by host MHC class I expression (4, 7, 8). The
MHC-dependent alterations in the Ly49 repertoire are
likely to reflect mechanisms that ensure that NK cells are
useful and self-tolerant in the context of the limited set of
MHC molecules the host happens to inherit. These pro-
cesses, and how they integrate with NK cell maturation,
are currently poorly understood.
Indeed, the NK cell differentiation process is itself poorly
understood. Unlike T cells, NK cells require neither a thy-
mus (9) nor V(D)J recombination (10) for their develop-
ment. Nevertheless, NK cells appear to be most closely re-
lated to the T cell lineage. Single clones of human CD34
 
bright
 
CD3
 
2
 
CD4
 
2
 
CD8
 
2
 
 thymocytes are capable of giving rise to
both NK and T cells (11). A population of similar pheno-
type isolated from mouse fetal thymocytes also appears able
to give rise to both NK and T cells (12). These immature
populations generally differentiate into T cells when placed
in a thymic environment and NK cells when placed into
other environments, suggesting that the environment in
which the cells develop influences their ultimate fate. Early
stages of NK cell development are generally thought to oc-
cur in the bone marrow, where NK cells make up 
 
z
 
2–4%
of the cells present. The presence of a proper bone marrow
microenvironment is thought to be necessary for proper
NK function, since mice treated with agents that affect the
bone marrow, such as 
 
89
 
Sr (13) or estradiol (14), are unable
to fully support the maturation of NK cells. However, this
microenvironment has proved exceedingly difficult to de-
fine. Nor is there a detailed picture of the different stages in
NK cell development.
A central issue in murine NK cell development concerns
how Ly49 receptor expression is coupled to NK cell matu-
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ration and education processes. Several models can be en-
visaged. One possibility is that all Ly49 receptors to be ex-
pressed by an individual NK cell are initially expressed
more or less simultaneously at a specific stage of differentia-
tion. Such a pattern would fit well with models in which
Ly49 receptor expression precedes selection steps or anergy
induction processes that result in a self-tolerant yet sensitive
population of mature NK cells (6). A second possibility is
that Ly49 receptor expression occurs successively, such that
a developing NK cell gradually accumulates receptors. This
pattern of expression would be consistent with models in
which NK cell education is directly coupled with receptor
gene induction. For example, as the NK cell accumulates
receptors, it may be concurrently tested for whether the
expressed receptors react with self–MHC class I molecules,
with a positive test causing termination of new receptor
expression (and possibly maturation of the NK cell; refer-
ence 6). A third possibility is that all Ly49 receptors are ini-
tially expressed in an NK cell progenitor, and expression of
some of these receptors is subsequently extinguished.
In vitro models of NK cell maturation have been as-
sessed, but no induction of new Ly49 receptor expression
was observed in these studies (reference 15 and Dorfman,
J.R., and D.H. Raulet, unpublished data). Hence, after doc-
umenting the ontogeny of Ly49 receptor expression, we
have investigated NK cell maturation and Ly49 receptor ex-
pression in vivo with the use of a cell transfer protocol,
similar to that used in establishing the sequence of cell dif-
ferentiation steps in thymic T cell development (16, 17).
NK cell subsets bearing an allotypic Ly5 marker were trans-
ferred to sublethally irradiated mice. After time for subse-
quent maturation, the phenotype of progeny cells was de-
termined. The results provide evidence for intermediates in
NK cell differentiation in which expression of Ly49 recep-
tors is ongoing. The pattern of expression suggests that Ly49
receptors may be expressed successively rather than in a
single burst, and that receptor expression, once it occurs, is
quite stable. Finally, the results indicate that different rules
govern induction of different Ly49 receptors, and raise the
possibility that there may be a nonrandom order in which
different Ly49 genes are induced.
 
Materials and Methods
 
Mice.
 
C57BL/6NCr (B6) mice were bred in the animal facil-
ity of the University of California (Berkeley, CA). B6 Ly5.1 mice
were purchased from the National Cancer Institutes (Frederick,
MD) where they are listed as B6 Ly5.2 mice according to the
previous nomenclature. BALB.B mice were kindly provided by
Dr. I. Weismann (Stanford University, Palo Alto, CA).
 
Antibodies and Reagents.
 
Anti-CD4 (RL-172; reference 18),
anti-CD8 (AD4-15; reference 19), anti–class II (I-A
 
b,d
 
)
 
 
 
(BP107;
reference 20), anti-NK1.1 (PK136; reference 21), anti-CD3 (22),
anti-FcR
 
g
 
II/III (2.4G2; reference 23), and the Ly49A-specific
mAb A1 (24) have all been described. The anti-Ly49A mAb JR9-
318 (25) was kindly provided by Dr. J. Roland (Institut Pasteur,
Paris, France). The mAb SW5E6 (26, 27) that recognizes both
Ly49C and Ly49I was generously provided by Drs. Vinay Kumar
 
and Michael Bennett (University of Texas, Dallas, TX) and the
hybridoma producing the anti-Ly49G2 mAb 4D11 (28) was pur-
chased from American Type Culture Collection (Rockville, MD).
Antibodies were purified from hybridoma supernatants by affinity
chromatography over protein A–sepharose or protein G–agarose
except JR9-318, which was purified from ascites by ammonium
sulfate fractionation followed by ion exchange chromatography.
Antibodies were conjugated to fluorescein, biotin, R-PE, or allo-
phycocyanin. The following reagents were purchased: streptavi-
din tricolor (Caltag Laboratories, South San Francisco, CA),
streptavidin RED613 (GIBCO BRL, Gaithersburg, MD), and,
for some experiments, anti-NK1.1 PE (PharMingen, San Diego,
CA), anti-CD3-FITC, and anti-CD3 biotin (GIBCO BRL).
 
Isolation of NK Cell Subsets for Transfers.
 
Splenocytes from 40–150
B6 mice aged 18–45 d were pooled and then enriched for NK
cells under aseptic conditions as described below. For contami-
nant control experiments, splenocytes were also isolated from 15–
30 B6 Ly5.1 mice and enriched for NK cells. In brief, cells were
passed over nylon wool treated with guinea pig complement,
rabbit complement, and anti-CD4, anti-CD8, anti–I-A
 
b
 
 antibod-
ies. Viable cells were recovered and stained for NK1.1, CD3
 
e
 
,
Ly49A, Ly49C/I and Ly49G2. The stained populations were
sorted on an ELITE flow cytometer (Coulter Immunology, Hi-
aleah, FL). Three- or four-color sorting was used, with different
antibodies conjugated to the same fluorescent dye as needed. All
isolated populations were sorted NK1.1
 
1
 
CD3
 
2
 
 except in some
replicates of the Ly49A
 
2
 
C
 
2
 
G2
 
1
 
I
 
2
 
 (Ly49G2 single positive cell)
experiments and one replicate of the Ly49A
 
1
 
C
 
2
 
G2
 
2
 
I
 
2
 
 (Ly49A
single positive cell) experiments. In these cases, the NK1.1
 
1
 
 pop-
ulation was sorted without any selection against residual NK1.1
 
1
 
CD3
 
1
 
 cells. NK cell subsets isolated from 4–10-d-old mice were
isolated in the same manner without use of the complement kill.
 
In Vivo Transfer and Subsequent Analysis of Isolated NK Subsets.
 
Cells were recovered from the flow cytometer, counted on a he-
macytometer and then injected intraveneously (subocularly) into
Ly5 congenic mice under metofane
 
 
 
anesthesia 2–4 h after they
received a single sublethal irradiation dose (600 RAD). After 10 d,
spleens and often thymuses were excised and analyzed. No purifi-
cation of splenocytes was necessary. All samples were preincu-
bated with anti-FcR
 
g
 
II/III antibody to block FcR
 
g
 
II/III-medi-
ated binding. Donor cells were never found in thymuses (
 
<
 
1/
10,000 events,
 
 n 
 
5 
 
4 for Ly49A
 
2
 
C
 
2
 
G2
 
2
 
I
 
2
 
 NK cell–injected mice).
When spleens were analyzed 20 d after transfer, splenocytes were
enriched for donor cells by passage over nylon wool before analy-
sis. Flow cytometry was performed on a flow cytometer (model
XL-MCL; Coulter Immunology). HBSS-injected controls were
analyzed in parallel in each experiment and few or no donor-type
events were detected in these mice.
 
Isolation and Transfer of Fetal Liver and NK-depleted Bone Marrow
Cells.
 
Fetal liver cells were isolated from day 14 B6 fetuses.
Bone marrow cells were isolated from 4-wk-old B6 mice by irri-
gation of the femurs and tibias and were incubated with PK136-
biotin followed by streptavidin conjugated magnetic microbeads
followed by passage over a steel wool column using a magnetic
activated cell sorting (MACS) apparatus (all MACS beads and ap-
paratuses were purchased from Miltenyi Biotech GmbH, Sunny-
vale, CA). Conditions were chosen that resulted in the loss of
Ly49C/I
 
1
 
 cells from bone marrow cells and NK-enriched sple-
nocytes in pilot experiments. Fetal liver cells and NK-depleted
bone marrow cells were injected into lethally irradiated (980
RAD) B6 Ly5.1 mice as described above for NK subsets. 10–12
wk after reconstitution, donor origin NK cells in spleens from
host mice were analyzed for Ly49 receptor expression. 
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Results
 
The Proportion of NK Cells Expressing Each Ly49 Receptor
Increases during Ontogeny.
 
Cells with the NK phenotype
(NK1.1
 
1
 
CD3
 
2
 
) were enriched from splenocytes of B6
mice of various ages, and the percentage of NK cells that
stained with each of three Ly49 receptor-specific antibodies
was assessed. The percentage of NK cells expressing any
particular Ly49 receptor increased over ontogeny, reaching
appreciable levels by 2–3 wk of age, and reaching adult lev-
els at 6–8 wk of age (Fig. 1). A similar pattern was observed
for NK1.1
 
1
 
CD3
 
2
 
 cells from the bone marrow, except that
smaller percentages stained with the antibodies at each age
point studied (data not shown).
The timing of the appearance of Ly49
 
1
 
 NK cells in the
spleen closely matches the appearance of NK activity in the
mouse as assayed by their competence to reject bone mar-
row grafts (17–22 d; reference 29) or as assayed by the ap-
pearance of in vitro NK activity in the spleen (18–26 d;
references 14, 30). These findings raised the possibility that
the NK cells found in younger (
 
,
 
3 wk) mice, few of
which express Ly49 receptors, are largely inactive. How-
ever, it is not known whether the Ly49
 
2
 
 NK cells in
young mice are deficient in functional activity, as suggested
by Hackett et al. (14), or are simply too infrequent to me-
diate substantial NK cell activity, as suggested by their lower
absolute cell numbers in the spleen during early life (data
not shown).
 
Acquisition of Ly49 Receptor Expression by NK1.1
 
1
 
Ly49A
 
2
 
C
 
2
 
G2
 
2
 
I
 
2
 
 Cells.
 
NK cells that express the tested
Ly49 receptors could arise directly from NK1.1
 
2
 
 progeni-
tor cells. Alternatively, they could arise from NK1.1
 
1
 
CD3
 
2
 
cells that do not express these Ly49 receptors. We employed a
cell transfer system to assess whether NK1.1
 
1
 
CD3
 
2
 
 cells that
do not express the tested Ly49 receptors can subsequently
acquire them.
Splenocytes from 40–150 B6 mice of 18–45 d of age
were pooled, enriched for NK cells, and then stained and
sorted for NK1
 
1
 
CD3
 
2
 
 Ly49A
 
2
 
C
 
2
 
G2
 
2
 
I
 
2
 
 cells. Sorted
populations were reanalyzed at the completion of the sort;
the reanalysis of a representative experiment is shown in
Fig. 2
 
a
 
. Sorted cells were injected i.v. into B6 Ly5.1 mice
Figure 1. Ontogeny of expression of Ly49 receptors by splenic NK
cells. Early splenic NK1.11CD32 cells do not express Ly49 receptors and
gradually acquire them during postnatal life. The proportion of
NK1.11CD32 cells (6 SD where applicable) expressing the indicated re-
ceptor(s) is shown. The same trends were not observed when splenic
NK1.11 T (NK1.11CD31) cells were examined (data not shown).
Figure 2. Ly49A2C2G22I2
NK cells express some Ly49 re-
ceptors after in vivo transfer.
Ly49A2C2G22I2 NK cells were
purified by cell sorting from B6-
derived, NK-enriched spleno-
cytes and then transferred into
Ly5 congenic mice as described
in the Materials and Methods. (a)
Post-sort analysis (before trans-
fer) from a representative experi-
ment. (b and c) Splenocytes from
an HBSS injected control (b) or a
recipient (c) were stained for
Ly5.2, the donor marker. (d–f)
Donor-derived cells were stained
for NK1.1 vs. Ly49A (d),
Ly49C/I (e), or Ly49G2 ( f).
Numbers indicate the percentage
of events in the corresponding
quadrant except the number in
parentheses, which indicates the
percentage of donor NK1.11
cells in the corresponding quad-
rant. Cells in the donor gate also
failed to stain with antibody spe-
cific for the host-type Ly5.1 allo-
type (not shown). 
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2–3 h after the mice were sublethally irradiated. After 10 d,
the spleens of the host mice were excised and splenocytes
were stained without enrichment. Donor cells were recog-
nized by an anti-Ly5.2 antibody, and generally constituted
 
z
 
0.5% of the splenocytes (Fig. 2, 
 
b 
 
and 
 
c
 
). The donor cells
were generally 
 
.
 
90% NK1.1
 
1
 
. The number of donor-type
cells recovered ranged from 2–20% of the number injected,
with an average of 
 
z
 
10%.
10 d after transfer, 
 
z
 
90% of the donor-derived cells
were NK1.1
 
1
 
CD3
 
2
 
 cells, suggesting that the donor NK
phenotype is quite stable. No CD3
 
1
 
 donor cells were de-
tected in the spleen and no donor cells of any type were
detected in the thymuses of the recipient mice. Signifi-
cantly, although essentially none of the donor-derived cells
expressed Ly49A, Ly49C/I, or Ly49G2 at the time of
transfer, an appreciable fraction expressed Ly49C/I (Fig. 2 
 
e
 
)
or Ly49G2 (Fig. 2 
 
f
 
) after transfer. Surprisingly, none of
the donor cells expressed Ly49A after transfer (Fig. 2 
 
d,
 
 and
see below).
The results of 11 replicates of this experiment are sum-
marized in the first line of Table 1, including two experi-
ments in which donor cells of B6 origin were injected into
BALB.B mice, and one experiment in which donor cells of
B6 Ly5.1 origin were injected into B6 mice. Ly49C/I and
Ly49G2 receptors were consistently expressed by a signifi-
cant fraction of cells after transfer, whereas no significant
expression of Ly49A was observed in any of the experi-
ments. Control mice were routinely injected with HBSS in
parallel and then analyzed at the same time that host mice
were analyzed. Few or no cells that stained with the donor-
specific antibodies were detected in these mice. Further-
more, control antibodies specific for the host cell marker
did not stain the donor-derived cells, indicating that the
staining procedure was specific for donor-type cells. These
results suggest that Ly49C/I and Ly49G2 expression was
induced on a fraction of transferred splenic NK1.1
 
1
 
CD3
 
2
 
cells, whereas Ly49A was not. It is notable that Ly49C and
Ly49I receptors are H-2
 
b
 
–reactive receptors (31, 32; Hanke,
T., and D.H. Raulet, unpublished data), and hence self-reac-
tive in these experiments, whereas Ly49G2 is not H-2
 
b
 
reactive (5). Therefore, the capacity of a receptor to be ex-
pressed after transfer is not dependent on it being self-spe-
cific.
 
Expression of a Ly49 Receptor Is Stable upon In Vivo Trans-
fer.
 
As shown above, Ly49A
 
2
 
C
 
2
 
G2
 
2I2 NK cells can give
rise to Ly49C/G2/I1 NK cells. One possible interpretation
of this observation is that cells are constantly turning Ly49C,
Ly49G2, and/or Ly49I on and off. To address this possibil-
ity, we purified populations of NK cells expressing Ly49A,
Ly49C/I, or Ly49G2. These populations were transferred
individually into Ly5-congenic mice. In representative ex-
periments, NK1.11 cells expressing Ly49A (Fig. 3 a),
Ly49C/I (Fig. 3 b), or Ly49G2 (Fig. 3 c) were purified.
Cells from each sort were injected into sublethally irradi-
ated B6 Ly5.1 mice, and splenocytes from the recipient
mice were analyzed after 10 d. As can be readily seen, the
large majority of cells of donor origin continued to express
the selected receptor even 10 d after in vivo transfer (Fig. 3).
Whether or not this stability extends beyond 10 d remains
untested.
Failure of Ly49A2C2G22I2 NK Cells to Acquire Ly49A
after Transfer. It was surprising that donor NK1.11 Ly49A2
C2G22I2 cells specifically failed to express Ly49A after
transfer. The Ly49A stain was effective, because host-derived
Ly49A1 NK cells were readily detectable in the same sam-
ples (not shown). Furthermore, Ly49A1 NK cells were eas-
ily detected among donor-type cells after injection of un-
sorted, enriched NK cells regardless of whether or not
these cells had been stained in the same manner as was used
for the sorting experiments (not shown). Also, Ly49A1 NK
Figure 3. Cells expressing particular Ly49 receptors before transfer
continue to express them after in vivo transfer. B6 NK cells sorted for ex-
pression of the Ly49A (a), Ly49C/I (b), or Ly49G2 (c) receptors were
transferred into B6-Ly5 congenic mice. Analyses of the cells before trans-
fer (left panels) and 10 d after transfer (right panels) are shown. Note that
these analyses were performed on different days on different flow cytom-
eters; therefore, staining intensities are not directly comparable. Numbers in
each quadrant indicate percentages of total events in each quadrant, and
numbers in parentheses are percentages of donor-derived NK1.11 cells. On
the right side of the panels, a summary is shown of all experiments in
which NK cells expressing the indicated receptor were transferred.
Ly49G2 summary values include values from experiments in which
Ly49G2 single positive cells were injected, while Ly49A values are de-
rived exclusively from experiments in which Ly49A single positive cells
were transferred (see Table 2). a and Fig. 4 contain data derived from a
single experiment. Values are indicated as percentages of donor derived
NK1.11 cells 6 SD.613 Dorfman and Raulet
cells were readily detectable when sorted Ly49A1 NK cells
were injected (Fig. 3 a). Thus, the failure to detect Ly49A1
NK cells after transfer of Ly49A2C2G22I2 NK cells does
not reflect an inability to detect Ly49A expression.
The possibility was considered that the failure to detect
Ly49A1 NK cells after transfer of NK1.11Ly49A2 cells re-
flected the relatively advanced age (18–45 d old in different
experiments) of the donor mice. However, transferred
Ly49A2C2G22I2 NK cells from 4–10-d-old donors also
failed to produce significant numbers of Ly49A1 NK cells
(Table 1). Since most endogenous Ly49A1 cells appear in
normal mice after 10 d of age (Fig. 1), it appears unlikely
that precursors of Ly49A1 NK cells have already disap-
peared by this age.
Another possibility was that acquisition of Ly49A is de-
layed compared with the other receptors and had not yet
occurred by 10 d after transfer. However, even 20 d after
transfer of Ly49A2C2G22I2 NK cells no Ly49A1 NK cells
could be detected (Table 1). In normal mice, Ly49A ex-
pression reaches nearly adult levels within 20 d of birth
(Fig. 1). There was also the possibility that Ly49A expres-
sion occurs immediately after transfer and is subsequently
rapidly extinguished. However, as shown above, trans-
ferred Ly49A1 NK cells persist and faithfully continue to
express Ly49A 10 d after transfer (Fig. 3 a). Therefore, it is
unlikely that the expression of Ly49A after transfer is tran-
sient. Finally, it seemed possible that irradiated mice repre-
sent a nonpermissive environment for differentiation of
Ly49A1 NK cells from Ly49A2 progenitor cells. However,
irradiated mice reconstituted with NK cell–depleted bone
marrow cells generated normal numbers of donor-type
Ly49A1 NK cells 12 wk after reconstitution (Table 1).
Similar results were obtained when fetal liver cells were
transferred (data not shown).
The above experiments and considerations suggest that
irradiated mice are permissive for acquisition of Ly49A by
differentiating NK cells, and that the failure to detect these
cells after transfer of Ly492NK1.11 cells is unlikely to re-
flect inadequate detection procedures. It thus appears likely
that splenic NK1.11CD32 cells are competent to initiate
expression of some Ly49 receptors (Ly49C/I and Ly49G2),
whereas initiation of Ly49A expression by these cells either
does not occur or is grossly delayed (see Discussion).
Successive Expression of Ly49 Receptors. Although the donor
cells in the above transfer experiments were Ly49A2C2
G22I2 cells, it is highly likely that at least some of them ex-
pressed one of the at least five other members of the Ly49
receptor family, for which specific antibodies were not
available. With this in mind, two nonmutually exclusive
explanations can be considered for the initiation of Ly49C/I
and Ly49G2 receptor expression after transfer of Ly49A2
C2G22I2 NK cells. The first is that the Ly49-expressing
cells after transfer were all derived from transferred NK1.11
progenitor cells that did not express any Ly49 receptors.
The competing possibility is that some or all of the Ly49C/
I1 and Ly49G21 cells after transfer were derived from NK
cells that already expressed other Ly49 family members at
the time of transfer. If this were the case, it would imply
that expression of new Ly49 receptors on NK lineage cells
occurs rather gradually and successively.
Figure 4. Ly49A single positive (Ly49A1C2G22I2) NK cells express
Ly49C/I and Ly49G2 after in vivo transfer. Ly49A1C2G22I2 NK cells
were purified by cell sorting from B6-derived, NK-enriched splenocytes
and then transferred into Ly5 congenic mice as described in Materials and
Methods. (a) Post-sort analysis (before transfer) from a representative ex-
periment. (b) Donor-derived cells from the same experiment 10 d after
transfer were stained for NK1.1 vs. Ly49A, Ly49C/I or Ly49G2. Numbers in
each quadrant indicate percentages of events in each quadrant except
numbers in parentheses, which are percentages of donor-derived NK1.11
cells. Data in this figure and Fig. 3 a are derived from the same experiment.
Table 1. Summary of Transfer Experiments with 
Ly49A2C2G22I2 NK Cells or Bone Marrow Cells
Resulting cells, 10 d after injection
Injected cells
Percent
Ly49A1
Percent
Ly49C/I1
Percent
Ly49G21
Ly49A2C2G22I2 (n 5 11)
seven sorts;
from 18-45-d-old mice
1.0 6 0.7 27.3 6 5.3 18.9 6 7.8
Ly49A2C2G22I2 (n 5 1)
from 4–10-d-old mice
0.0 25.5 25.2
Ly49A2C2G22I2 (n 5 1)
20 d after injection
1.2 48.1 28.4
NK-depleted bone
marrow (n 5 2)
12 wk after injection
16.8 6 0.4 40.4 6 3.5 47.0 6 0.5
Values represent average percentages of donor-derived NK1.11 cells
that express the relevant receptor after in vivo transfer. Values are 6SD
where applicable.614 Acquisition of Ly49 Receptor Expression
To investigate whether Ly49 receptors can be expressed
successively, we purified Ly49A1C2G22I2 cells (referred
to below as Ly49A single positive cells) and transferred
them to Ly5 congenic mice. After 10 d, an appreciable
fraction of the cells expressed Ly49C/I or Ly49G2 (Fig. 4,
Table 2). In other experiments, Ly49A2C2G21I2 cells (re-
ferred to below as Ly49G2 single positive cells) were puri-
fied and transferred. 10 d after transfer, an appreciable frac-
tion of these cells expressed Ly49C and/or Ly49 (Table 2).
Thus, splenic NK cells that already express at least one
Ly49 receptor were capable of expressing new Ly49 recep-
tors after in vivo transfer. These data suggest that Ly49 re-
ceptors may be expressed successively during NK cell devel-
opment. The newly expressed receptors that we observed
included receptor(s) that are self-specific (Ly49C and/or
Ly49I) and a receptor that is not self-specific (Ly49G2).
Thus, there was no correlation between the presence of a
MHC class I ligand for the newly expressed receptor and the
ability of the NK cell to initiate its expression. However,
when Ly49G21 NK cells were transferred, few or none of
them expressed Ly49A 10 d after transfer (Table 2). These
data extend the earlier results indicating that transferred
NK1.11Ly49A2 cells do not give rise to Ly49A1 cells.
Ly49-expressing Cells after Transfer Are Not Derived from
Contaminating Ly49C/I or G21 Cells or NK1.12 Cells in the
Transferred Population. The previous data suggest that NK1.11
CD32 cells that do not express a Ly49 receptor can acquire
it after in vivo transfer. However, it remained possible that
the Ly49C/I or G21 cells after transfer were derived not
from the majority Ly49A2C2G22I2 NK1.11 CD32 popu-
lation, but from contaminating cells in the inoculum,
which might selectively survive or expand after transfer.
One possibility was that the Ly49C/I or G21 cells after
transfer were derived from small numbers of contaminating
Ly49C/I or G21 cells in the inoculum. To address this pos-
sibility, the inoculum population (Ly49A2C2G22I2 NK
cells from B6 mice) was purposefully contaminated with a
defined percentage of sorted Ly49C/I or G21 NK cells
from B6-Ly5.2, as diagrammed in Fig. 5. The Ly5 differ-
ence allowed us to evaluate the contribution of the con-
taminants to the resulting Ly49C/I or G21 NK cells after
transfer. To distinguish both types of donor cells from host-
type NK cells after transfer, the cells were inoculated into
irradiated BALB.B recipients that fail to express NK1.1 on
their NK cells. Thus, cells that expressed NK1.1 were sure
to be of donor origin, and whether they were derived from
the added Ly49C/I or G21 contaminant population could
be ascertained based on Ly5 expression.
Post-sort analysis indicated that the Ly49A2C2G22I2 NK
cells purified from B6 (Ly5.2) splenocytes contained <0.1%
Ly49C/I or G21 NK contaminants (not shown). This pop-
ulation was spiked with sorted Ly49C/I or G21 NK cells
from B6-Ly5.1 mice, so as to achieve 2% contamination, a
.20-fold excess (2%/<0.1%) compared with B6-derived
contaminants (Table 3). After flow cytometric analysis to
confirm the contamination level, the cell mixture was in-
oculated into BALB.B mice. Although the contaminant
population accounted for >95% of the Ly49C/I or G21
NK cells at the time of injection, 10 d after transfer they
accounted for only z15% of the resulting Ly49C/I1 NK
cells and 5–20% of the resulting Ly49G21 cells (Table 3).
These data indicate that contaminating Ly49C/I or G21
NK cells in the inoculum cannot account for the large ma-
jority of Ly49C/I or G21 NK cells in the population after
transfer, especially when it is recalled that the Ly5.11 con-
taminating cells were added at a .20-fold excess compared
with contaminating B6 origin Ly49C/I or G21 cells. There-
fore, the large majority of Ly49C/I or G21 NK cells after
transfer were derived from Ly49A2C2G22I2 cells in the
inoculum.
Figure 5. Experimental design to assess contribution of cellular con-
taminants to Ly49C/I or G21 populations present after cell transfer.
Ly49A2C2G22I2 NK1.11 cells were purposefully contaminated with
tracer Ly5 congenic cells, either Ly49C/I or G21 NK cells or NK1.12
cells, and transferred into irradiated BALB.B recipients. The contribution
of the added contaminating cells to the population 10 d after transfer was
then determined.
Table 2. NK Cells Already Expressing an Ly49 Receptor Remain 
Capable of Expressing New Receptors After In Vivo Transfer
Injected cells
Resulting cells, 10 d after injection
Percent
Ly49A1
Percent
Ly49C/I1
Percent
Ly49G21
Ly49A1C2G22I2 (n 5 2)
two sorts
99.2, 96.3* 8.6, 27.8 26.7, 87.0
Ly49A2C2I2G21 (n 5 3)
three sorts
1.7 6 2.5 22.6 6 3.6 92.2 6 7.7*
Values indicate the precentages of donor NK1.11 cells that express the
relevant receptor(s) after in vivo transfer, 6SD where applicable.
*These values are included in the summary data shown in Fig. 3.615 Dorfman and Raulet
A similar strategy (Fig. 5) was used to address the possi-
bility that the Ly49C/I or G21 NK cells observed after
transfer arose from contaminating NK1.12 cells in the in-
oculum. The spleen contains hematopoietic stem cells and
possibly other more restricted lymphoid progenitors, so it
was possible that these cells differentiated into Ly49C/I or
G21 NK cells after transfer. Post-sort analysis indicated that
a purified population of B6-derived Ly49A2C2G22I2 NK
cells contained z2.1% NK1.12 cells, a value similar to that
seen in other experiments (e.g., 1.4% in Fig. 2). NK1.12
splenocytes from B6-Ly5.1 mice were added to this popu-
lation so as to achieve 5% contamination, a 2.5-fold excess
compared with the NK1.12 contaminants already present.
The added NK1.12 splenocytes had been sorted from a
population that was initially enriched for NK cells using the
same procedure as was used for the NK1.11 population.
After flow cytometric analysis to confirm the cell composi-
tion (not shown) the mixture was injected into irradiated
BALB.B mice. 10 d after transfer, NK1.11 (donor) cells were
tested for expression of Ly5 markers (Fig. 6). Although
70% of the contaminating NK1.12 cells in the inoculum
were from the Ly5.11 donor, essentially none (,2%) of the
donor-derived NK1.11 cells after transfer were Ly5.11.
Significant numbers of Ly5.11 cells were observed in only
one of the two recipients, and these were overwhelmingly
NK1.12 (Fig. 6). None of the Ly5.11 cells after transfer de-
tectably expressed Ly49C/I or Ly49G2. We conclude that
neither contaminating NK1.12 precursors, nor contami-
nating Ly49C/I or G21 cells, can account for the vast ma-
jority of Ly49C/I or G21, NK1.11 cells observed after
transfer of Ly49A2C2G22I2 NK1.11 cells. It follows that
the Ly49C/I or G21 cells after transfer were derived from
NK1.11 Ly49A2C2G22I2 cells in the inoculum.
Discussion
Ly491 Cells Appear Gradually during Ontogeny Among
Splenic NK Cells and Their Appearance Is Associated with the
Appearance of NK Activity. During ontogeny, the propor-
tion of NK1.11CD32 cells expressing each Ly49 receptor
starts very low and then gradually rises, reaching adult lev-
els by approximately six weeks of age. At the adult stage,
.80% of NK cells express one or more of the detectable
Ly49 receptors (data not shown). Functional tests revealed
that the 20% that were negative for Ly49A, C, G, and I
were nevertheless as lytic against YAC-1 tumor target cells
as Ly49A, C, G2 or I1 effector cells (data not shown), and
it is likely that many of these cells express one of the five
other Ly49 receptors that have been identified that are not
detected with the antibodies employed here. In contrast,
since so few NK1.11 CD32 cells in young mice stained
with the anti-Ly49 antibodies, it appears likely that many
of these cells fail to express any Ly49 receptors. Whether
these cells are nonfunctional and/or immature, or express
inhibitory receptors other than Ly49 receptors, such as
CD94/NKG2 heterodimers (33, 34), remains to be deter-
mined.
Initiation of Ly49 Receptor Expression. The transfer experi-
ments demonstrate that Ly49A2C2G22I2 NK1.11 cells can
initiate Ly49 receptor expression after transfer in vivo (Fig.
2). The control experiments argue persuasively that the
Ly49C/I1 or G21 cells did not arise from either contami-
nating Ly49C/I or G21 cells or NK1.12 cells in the inocu-
lum (Figs. 5 and 6, Table 3). In the case of transferred NK
cells from young (4–10 d old) mice, it is likely that most of
Table 3. Contribution of Added Contaminants to NK Cell Populations after In Vivo Transfer
Recipient
Inoculum Post-transfer
Percent Ly49C/G2/I1 cells Percent Ly49C/I1 cells Percent Ly49G21 cells
Ly5.2 (B6 origin) Ly5.1 (added) Ly5.2 (B6 origin) Ly5.1 (added) Ly5.2 (B6 origin) Ly5.1 (added)
1 ,0.1% 2% 26.2% 4.5% 35.5% 2.2%
2 ,0.1% 2% 23.4% 3.9% 23.8% 5.5%
Figure 6. NK cells do not arise from splenic NK1.12 contaminants in
the starting Ly49A2C2G22I2 NK population. Cells were purified, mixed
and inoculated into BALB.B mice as described in Fig. 5. NK cells of B6
and B6 Ly5.1 (marked contaminant) origin were detected by their expres-
sion of NK1.1, which is not expressed in BALB.B mice. NK cells derived
from the marked contaminant NK1.12 population were detected by their
coordinate expression of Ly5.1 and NK1.1. The marked contaminant
cells represented 70% of NK1.12 cells in the injected population 10 d ear-
lier (not shown). However, few or none of the NK1.11 cells after transfer
were derived from these contaminants. Additionally, none of the Ly49C/
G2/I1 NK cells were of B6 Ly5.1 origin (not shown). Numbers denote
the percentages of total cells present in each quadrant. Ly5.12 cells in-
clude both host origin and B6 origin cells. The oddly shaped NK1.12
Ly5.12 population was an artifact of the flow cytometry analysis, as shown
by parallel analysis of BALB.B mice inoculated with HBSS.616 Acquisition of Ly49 Receptor Expression
the transferred donor cells failed to express any Ly49 recep-
tors, suggesting that Ly492 NK1.11 cells can initiate Ly49
receptor expression within 10 d after in vivo transfer. In
the case of the older (18–45 d old) donors, the transferred
population probably contained substantial numbers of cells
expressing undetected Ly49 receptors, so it cannot be di-
rectly surmised from this experiment whether the Ly49 ex-
pression was initiated on transferred Ly492 or Ly491 cells.
However, the cumulative expression of Ly49 receptors was
demonstrated directly by transferring Ly49 single positive
cells (Fig. 4, Table 2). The extent of new receptor expres-
sion appeared similar to that of transferred Ly49A2
C2G22I2 NK cells (Table 1). These results provide support
for the notion that Ly49 receptor acquisition is a relatively
gradual process, rather than occurring in a burst. Notably,
the data as a whole also demonstrate that receptor expres-
sion occurs additively, rather than subtractively.
Whether the particular NK cells that successively express
Ly49 receptors are functionally active before transfer has
not been established. The transferred NK cell population
includes functional (mature) NK cells, but it is plausible
that some of the transferred cells were nonfunctional or im-
mature, and that it was these cells that gave rise to new
Ly49 receptor expression after transfer. Alternatively, it re-
mains possible that even functionally active NK cells can
express new Ly49 receptors. Whether such a process would
be advantageous to the animal is arguable in the context of
available information. New Ly49 expression by active ma-
ture NK cells may represent a threat to the animal, since
the NK cells might eventually adapt to the class I MHC al-
terations that occur in tumor cells or virus-infected cells
(35). For example, many tumor cells have been observed to
extinguish expression of some but not all cellular class I
molecules (36). It would seem counterproductive if NK
cells could adapt by expressing new receptors specific for
the remaining class I molecules on these tumor cells. On
the other hand, the expression of new receptors by mature
NK cells could endow the NK compartment with the ca-
pacity to adapt to changing MHC environments, as might
occur as NK cells traffic to different tissues where class I
MHC levels may vary considerably.
The kinetics of receptor expression observed here fulfill
a critical prediction of the sequential receptor expression
model of NK cell education, which posits that successive
receptor expression on developing NK cells is coupled with
ongoing testing of the reactivity of the receptors with self–
MHC class I molecules (4, 6, 37). Strong reactions with self–
MHC class I molecules would terminate the phase in which
receptor expression is initiated, and possibly stimulate mat-
uration of the NK cell. It must be acknowledged, however,
that while the results argue for successive expression of re-
ceptors on NK cells, they do not address whether interac-
tions with class I MHC molecules impact this process.
Therefore, it remains possible that receptors are expressed
successively, but that testing of these cells (e.g., selection)
does not occur until a later stage. A hybrid between these
models (38) proposes that developing NK cells may be per-
missive for initiating Ly49 receptor expression for only a
discrete time period in their development, during which
MHC class I engagement can terminate the process. Cells
that fail to achieve expression of self–MHC class I–specific
receptors in this time window would then be silenced.
Ly49 Receptor Expression, Once Initiated, Appears Stable.
As noted above, Ly49 receptor expression, once initiated, is
stable for at least 10 d in vivo, consistent with previous in
vitro results (39). Although 2–7% of the transferred Ly491
NK cell population were negative for the applicable Ly49
receptor 10 d after transfer (Fig. 3, Table 2), we suspect
that these cells may have arisen from contaminating NK
cells that did not express the relevant Ly49 receptor at the
time of transfer. Indeed, small numbers of NK1.11Ly492
cells could be detected in the donor Ly491 populations in
most experiments (Fig. 3). However, we cannot rule out
the possibility that small numbers of Ly491 cells extinguish
Ly49 expression by 10 d after transfer. Minimally, the data
argue that extinction of receptor expression is much rarer
after transfer than initiation of receptor expression, since
19–27% of donor cells initiated expression of a Ly49 recep-
tor after transfer, whereas only <2–7% of cells, if that, lost
receptor expression after transfer. The extent to which
Ly49 gene expression is stable in vivo over periods longer
than 10 d is untested.
The stability of Ly49 receptor expression, after initiation,
seems consistent with the demands of NK cells to maintain
self-tolerance. If self–MHC class I–specific receptors were
readily extinguished, NK cells would be constantly revert-
ing to an autoaggressive state. However, a previous study
with MHC-mosaic mice indicates that NK cell tolerance
can be rapidly reversed when NK cells are cultured in the
absence of a relevant MHC ligand (40). Our data suggest
that this reversal in tolerance is unlikely to result from re-
pression of Ly49 receptor expression, since we found that
Ly49A1 and Ly49G21 NK cells maintained receptor ex-
pression in vivo, even in the absence of a ligand (e.g., Dd).
An alternative interpretation noted above is that during
their development, some NK cells never attain expression
of self-specific Ly49 receptors. These cells may be rendered
nonresponsive to autologous cells by a mechanism that
does not involve expression of self–MHC class I specific re-
ceptors, such as downregulation of receptors or signaling
pathways required for NK cell activation. Reversal of this
form of tolerance might occur when the MHC ligand is
absent, and/or in the presence of IL-2.
The Inability of Transferred Ly49A2 Cells to Initiate Expres-
sion of Ly49A. The specific failure of transferred Ly49A2
NK cells to give rise to Ly49A1 NK cells was unexpected.
The failure of Ly49A to be expressed was not obviously re-
lated to its inability to recognize H-2b molecules; Ly49G2
expression was initiated in the transfer experiments, and H-2b
mice lack a ligand for Ly49G2. Furthermore, expression of
both Ly49A and Ly49G2 occurs during normal NK cell
differentiation in H-2b mice (Fig. 1), and also during NK
cell differentiation after transfer of bone marrow stem cells
to irradiated mice (Table 1). The data suggest that splenic
NK1.11 Ly49A2 NK cells have impaired capacity to ini-
tiate expression of the Ly49A receptor, while retaining the617 Dorfman and Raulet
capacity to express at least some of the other Ly49 recep-
tors.
One possibility to explain the impaired capacity of trans-
ferred cells to initiate Ly49A expression is that there is a
specific sequence in which Ly49 genes are expressed, and
that Ly49A expression is normally initiated early in the
process. Initiation of Ly49A receptor expression may be
limited to the stage before NK progenitors express NK1.1,
or may occur on NK1.11 cells before such cells migrate to
the spleen. We found it difficult to obtain sufficient num-
bers of purified bone marrow Ly49A2NK1.11CD32 cells
to test the latter version of the hypothesis. Either of these
scenarios could account for our results, since our protocol
involved the transfer of splenic NK1.11CD32 cells that
may have already passed the stage where cells are permis-
sive for initiation of Ly49A expression. Alternatively, initi-
ation of Ly49A expression, unlike the other receptors tested,
may require an in vivo environment that is poorly repli-
cated in the early phases of bone marrow reconstitution in
irradiated mice or may be grossly delayed compared with
initiation of Ly49C, G2 or I expression.
In conclusion, the results reported here demonstrate a
successive acquisition of stable Ly49 receptor expression by
developing NK cells. The results have significance both for
the mechanisms that initiate receptor expression and the
education process that results in a useful NK repertoire.
The experimental system we employed may be useful for
examining the impact of Ly49 receptor engagement with
class I MHC ligands on subsequent Ly49 receptor gene ex-
pression in developing NK cells.
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